Analysts Set ICU Medical, Inc. (NASDAQ:ICUI) PT at $175.67

ICU Medical, Inc. (NASDAQ:ICUI) has earned a consensus recommendation of “Moderate Buy” from the five ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $175.6667.

ICUI has been the topic of several recent analyst reports. Piper Sandler lifted their target price on shares of ICU Medical from $153.00 to $172.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Monday. KeyCorp boosted their price objective on ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ICU Medical in a research report on Wednesday, October 8th.

Insider Activity

In related news, VP Virginia Ruth Sanzone sold 930 shares of ICU Medical stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $142.34, for a total value of $132,376.20. Following the sale, the vice president owned 5,456 shares of the company’s stock, valued at approximately $776,607.04. The trade was a 14.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Elisha W. Finney sold 1,285 shares of the company’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $140.42, for a total value of $180,439.70. Following the completion of the transaction, the director owned 3,995 shares in the company, valued at approximately $560,977.90. The trade was a 24.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.50% of the company’s stock.

Institutional Trading of ICU Medical

Several hedge funds have recently made changes to their positions in the company. Cullen Frost Bankers Inc. bought a new position in shares of ICU Medical during the 2nd quarter worth $38,000. SJS Investment Consulting Inc. raised its stake in ICU Medical by 41,000.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 411 shares of the medical instruments supplier’s stock valued at $49,000 after acquiring an additional 410 shares during the period. Covestor Ltd lifted its holdings in ICU Medical by 70.7% during the third quarter. Covestor Ltd now owns 570 shares of the medical instruments supplier’s stock valued at $68,000 after purchasing an additional 236 shares during the last quarter. Blue Trust Inc. boosted its position in ICU Medical by 17.6% during the second quarter. Blue Trust Inc. now owns 942 shares of the medical instruments supplier’s stock worth $124,000 after purchasing an additional 141 shares during the period. Finally, Smartleaf Asset Management LLC boosted its position in ICU Medical by 11.6% during the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after purchasing an additional 101 shares during the period. 96.10% of the stock is currently owned by institutional investors.

ICU Medical Trading Up 0.7%

NASDAQ ICUI opened at $156.17 on Monday. The company has a current ratio of 2.45, a quick ratio of 1.19 and a debt-to-equity ratio of 0.62. The business has a fifty day simple moving average of $145.37 and a 200 day simple moving average of $132.12. ICU Medical has a 12 month low of $107.00 and a 12 month high of $175.51. The firm has a market capitalization of $3.86 billion, a P/E ratio of -503.76 and a beta of 0.80.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.43 by $0.60. The firm had revenue of $533.30 million during the quarter, compared to analyst estimates of $511.46 million. ICU Medical had a negative net margin of 0.32% and a positive return on equity of 7.71%. The business’s revenue was down 8.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.59 EPS. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. On average, analysts predict that ICU Medical will post 4.11 EPS for the current fiscal year.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.